中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 12
Dec.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(12): 2932-2934

Association of sarcopenia with prognosis after transjugular intrahepatic portosystemic shunt in patients with liver cirrhosis

DOI: 10.3969/j.issn.1001-5256.2021.12.041

  • Department of Gastroenterology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China

  • Received Date: 2021-05-04
  • Accepted Date: 2021-05-24
  • Published Date: 2021-12-20
    Abstract
  • Sarcopenia is a common and insidious complication in patients with liver cirrhosis and is closely associated with the prognosis of patients with liver cirrhosis. Transjugular intrahepatic portosystemic shunt (TIPS) is an important method for the treatment of portal hypertension-related complications. More and more studies have shown that sarcopenia is associated with the prognosis of cirrhotic portal hypertension after TIPS. This article reviews the research on sarcopenia and its association with TIPS in China and globally, in order to explore the association between them and guide clinical treatment.

     

    • FullText(HTML)
  • loading
    • References(32)
  • [1]
    KAMIMURA H, SATO T, NATSUI K, et al. Molecular mechanisms and treatment of sarcopenia in liver disease: A review of current knowledge[J]. Int J Mol Sci, 2021, 22(3): 1425. DOI: 10.3390/ijms22031425.
    [2]
    The Chinese College of Interventionalists. CCI clinical practice guidelines: Management of TIPS for portal hypertension (2019 edition)[J]. J Clin Hepatol, 2019, 35(12): 2694-2699. DOI: 10.3969/j.issn.1001-5256.2019.12.010.

    中国医师协会介入医师分会. 中国门静脉高压经颈静脉肝内门体分流术临床实践指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2694-2699. DOI: 10.3969/j.issn.1001-5256.2019.12.010.
    [3]
    VIZZUTTI F, SCHEPIS F, ARENA U, et al. Transjugular intrahepatic portosystemic shunt (TIPS): Current indications and strategies to improve the outcomes[J]. Intern Emerg Med, 2020, 15(1): 37-48. DOI: 10.1007/s11739-019-02252-8.
    [4]
    NARDELLI S, LATTANZI B, TORRISI S, et al. Sarcopenia is risk factor for development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement[J]. Clin Gastroenterol Hepatol, 2017, 15(6): 934-936. DOI: 10.1016/j.cgh.2016.10.028.
    [5]
    PRAKTIKNJO M, CLEES C, PIGLIACELLI A, et al. Sarcopenia is associated with development of acute-on-chronic liver failure in decompensated liver cirrhosis receiving transjugular intrahepatic portosystemic shunt[J]. Clin Transl Gastroenterol, 2019, 10(4): e00025. DOI: 10.14309/ctg.0000000000000025.
    [6]
    TSIEN C, SHAH SN, MCCULLOUGH AJ, et al. Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent[J]. Eur J Gastroenterol Hepatol, 2013, 25(1): 85-93. DOI: 10.1097/MEG.0b013e328359a759.
    [7]
    ARTRU F, MIQUET X, AZAHAF M, et al. Consequences of TIPSS placement on the body composition of patients with cirrhosis and severe portal hypertension: A large retrospective CT-based surveillance[J]. Aliment Pharmacol Ther, 2020, 52(9): 1516-1526. DOI: 10.1111/apt.16080.
    [8]
    ARTRU F, LABREUCHE J, LOUVET A. TIPSS and reversal of sarcopenia, and TIPSS is a promising therapy for sarcopenia in cirrhosis-Authors' reply[J]. Aliment Pharmacol Ther, 2021, 53(1): 211-212. DOI: 10.1111/apt.16152.
    [9]
    NASEER M, TURSE EP, SYED A, et al. Interventions to improve sarcopenia in cirrhosis: A systematic review[J]. World J Clin Cases, 2019, 7(2): 156-170. DOI: 10.12998/wjcc.v7.i2.156.
    [10]
    DENT E, MORLEY JE, CRUZ-JENTOFT AJ, et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, diagnosis and management[J]. J Nutr Health Aging, 2018, 22(10): 1148-1161. DOI: 10.1007/s12603-018-1139-9.
    [11]
    PÁR A, HEGYI JP, VÁNCSA S, et al. Sarcopenia - 2021: Pathophysiology, diagnosis, therapy[J]. Orv Hetil, 2021, 162(1): 3-12. DOI: 10.1556/650.2021.32015.
    [12]
    NISHIKAWA H, FUKUNISHI S, ASAI A, et al. Sarcopenia and frailty in liver cirrhosis[J]. Life (Basel), 2021, 11(5): 399. DOI: 10.3390/life11050399.
    [13]
    BOJKO M. Causes of sarcopenia in liver cirrhosis[J]. Clin Liver Dis (Hoboken), 2019, 14(5): 167-170. DOI: 10.1002/cld.851.
    [14]
    WEST J, GOW PJ, TESTRO A, et al. Exercise physiology in cirrhosis and the potential benefits of exercise interventions: A review[J]. J Gastroenterol Hepatol, 2021. DOI: 10.1111/jgh.15474.
    [15]
    NISHIKAWA H, SHIRAKI M, HIRAMATSU A, et al. Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria[J]. Hepatol Res, 2016, 46(10): 951-963. DOI: 10.1111/hepr.12774.
    [16]
    THANDASSERY RB, MONTANO-LOZA AJ. Role of nutrition and muscle in cirrhosis[J]. Curr Treat Options Gastroenterol, 2016, 14(2): 257-273. DOI: 10.1007/s11938-016-0093-z.
    [17]
    MEYER F, BANNERT K, WIESE M, et al. Molecular mechanism contributing to malnutrition and sarcopenia in patients with liver cirrhosis[J]. Int J Mol Sci, 2020, 21(15). DOI: 10.3390/ijms21155357.
    [18]
    HANAI T, SHIRAKI M, MIWA T, et al. Effect of loop diuretics on skeletal muscle depletion in patients with liver cirrhosis[J]. Hepatol Res, 2019, 49(1): 82-95. DOI: 10.1111/hepr.13244.
    [19]
    SINCLAIR M. Controversies in diagnosing sarcopenia in cirrhosis-moving from research to clinical practice[J]. Nutrients, 2019, 11(10): 2454. DOI: 10.3390/nu11102454.
    [20]
    ESLAMPARAST T, MONTANO-LOZA AJ, RAMAN M, et al. Sarcopenic obesity in cirrhosis-The confluence of 2 prognostic titans[J]. Liver Int, 2018, 38(10): 1706-1717. DOI: 10.1111/liv.13876.
    [21]
    DHALIWAL A, ARMSTRONG MJ. Sarcopenia in cirrhosis: A practical overview[J]. Clin Med (Lond), 2020, 20(5): 489-492. DOI: 10.7861/clinmed.2020-0089.
    [22]
    WANG Z, LIU FQ. Research advances in hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. J Clin Hepatol, 2019, 35(12): 2824-2827. DOI: 10.3969/j.issn.1001-5256.2019.12.040.

    王重, 刘福全. 经颈静脉肝内门体分流术后肝性脑病的研究进展[J]. 临床肝胆病杂志, 2019, 35(12): 2824-2827. DOI: 10.3969/j.issn.1001-5256.2019.12.040.
    [23]
    PRAKTIKNJO M, BOOK M, LUETKENS J, et al. Fat-free muscle mass in magnetic resonance imaging predicts acute-on-chronic liver failure and survival in decompensated cirrhosis[J]. Hepatology, 2018, 67(3): 1014-1026. DOI: 10.1002/hep.29602.
    [24]
    GIOIA S, MERLI M, NARDELLI S, et al. The modification of quantity and quality of muscle mass improves the cognitive impairment after TIPS[J]. Liver Int, 2019, 39(5): 871-877. DOI: 10.1111/liv.14050.
    [25]
    BENMASSAOUD A, ROCCARINA D, ARICO F, et al. Sarcopenia does not worsen survival in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt for refractory ascites[J]. Am J Gastroenterol, 2020, 115(11): 1911-1914. DOI: 10.14309/ajg.0000000000000959.
    [26]
    ZOU SL, XU Y. Prognostic evaluation of transjugular intrahepatic portosystemic shunt in treatment of cirrhotic portal hypertension[J]. J Clin Hepatol, 2019, 35(1): 201-204. DOI: 10.3969/j.issn.1001-5256.2019.01.044.

    邹松龙, 胥莹. 经颈静脉肝内门体分流术治疗肝硬化门静脉高压症的预后评估[J]. 临床肝胆病杂志, 2019, 35(1): 201-204. DOI: 10.3969/j.issn.1001-5256.2019.01.044.
    [27]
    MONTANO-LOZA AJ. Clinical relevance of sarcopenia in patients with cirrhosis[J]. World J Gastroenterol, 2014, 20(25): 8061-8071. DOI: 10.3748/wjg.v20.i25.8061.
    [28]
    SHOREIBAH MG, MAHMOUD K, ABOUELDAHAB NA, et al. Psoas muscle density in combination with model for end-stage liver disease score can improve survival predictability in transjugular intrahepatic portosystemic shunts[J]. J Vasc Interv Radiol, 2019, 30(2): 154-161. DOI: 10.1016/j.jvir.2018.10.006.
    [29]
    RONALD J, BOZDOGAN E, ZAKI IH, et al. Relative sarcopenia with excess adiposity predicts survival after transjugular intrahepatic portosystemic shunt creation[J]. AJR Am J Roentgenol, 2020, 214(1): 200-205. DOI: 10.2214/AJR.19.21655.
    [30]
    MONTANO-LOZA AJ, DUARTE-ROJO A, MEZA-JUNCO J, et al. Inclusion of sarcopenia within MELD (MELD-Sarcopenia) and the prediction of mortality in patients with cirrhosis[J]. Clin Transl Gastroenterol, 2015, 6: e102. DOI: 10.1038/ctg.2015.31.
    [31]
    LATTANZI B, NARDELLI S, PIGLIACELLI A, et al. The additive value of sarcopenia, myosteatosis and hepatic encephalopathy in the predictivity of model for end-stage liver disease[J]. Dig Liver Dis, 2019, 51(11): 1508-1512. DOI: 10.1016/j.dld.2019.09.004.
    [32]
    SINCLAIR M, CHAPMAN B, HOERMANN R, et al. Handgrip strength adds more prognostic value to the model for end-stage liver disease score than imaging-based measures of muscle mass in men with cirrhosis[J]. Liver Transpl, 2019, 25(10): 1480-1487. DOI: 10.1002/lt.25598.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (376) PDF downloads(40) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return